8-K: Alzamend Neuro Faces Nasdaq Delisting After Failing to Meet Minimum Market Value Requirement

Alzamend Neuro is facing delisting from the Nasdaq Capital Market after failing to regain compliance with the minimum market value of listed securities requirement, but will appeal the decision.

Summary

• Alzamend Neuro sold 780 shares of Series B convertible preferred stock and warrants to purchase 780,000 shares of common stock to Ault Lending, LLC for $780,000.
• As of March 26, 2024, Ault Lending has purchased a total of 2,000 shares of Series B convertible preferred stock and warrants to purchase 2,000,000 shares for a total of $2 million.
• Ault Lending may purchase up to $6 million of Series B convertible preferred stock and warrants in total.
• The company was notified by Nasdaq on September 26, 2023, that its market value of listed securities fell below the $35 million minimum requirement.
• Alzamend Neuro was given until March 25, 2024, to regain compliance, but failed to do so.
• Nasdaq has scheduled the company's common stock for delisting on April 4, 2024, and will file a Form 25-NSE with the SEC.
• Alzamend Neuro will appeal the delisting decision, which will stay the suspension and allow the stock to continue trading on Nasdaq under the symbol ALZN pending the outcome of the appeal.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the potential delisting from Nasdaq, despite the ongoing appeal and recent capital raise. The failure to meet listing requirements is a significant concern.

Positives

• The company has secured an additional $780,000 in funding through the sale of Series B convertible preferred stock and warrants.
• The appeal process will allow the company's stock to continue trading on Nasdaq while the appeal is pending.

Negatives

• The company failed to regain compliance with Nasdaq's minimum market value of listed securities requirement.
• The company is facing potential delisting from the Nasdaq Capital Market.

Risks

• There is no guarantee that the company's appeal of the delisting decision will be successful.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.
• The company's ability to raise additional capital may be affected by the potential delisting.

Future Outlook

The company will appeal the delisting decision, and the stock will continue to trade on Nasdaq pending the outcome of the appeal. There is no assurance as to the success or outcome of the appeal.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining Nasdaq listing compliance, particularly in volatile market conditions. Many companies in the sector are facing similar challenges.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain the minimum market capitalization required for Nasdaq listing, especially during periods of market downturn or negative clinical trial results.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) have faced similar scrutiny regarding their stock performance and compliance with listing requirements, although they have not faced delisting.
• The $35 million minimum market value requirement is a standard benchmark for Nasdaq listing, and failure to meet this threshold is a common reason for delisting notices.

Related Party Transactions

• The Purchaser, Ault Lending, LLC, is an affiliate of the Company.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of value.
• Employees may experience uncertainty due to the company's financial situation and potential delisting.
• The company's ability to raise capital and fund operations may be impacted.

Next Steps

• The company will submit an appeal of the delisting decision to a Hearings Panel by April 2, 2024.
• The company will await the decision of the Hearings Panel regarding the appeal.
• The company's stock will continue to trade on Nasdaq under the symbol ALZN pending the outcome of the appeal.

Key Dates

Keywords

delisting, Nasdaq, market value, Series B convertible preferred stock, warrants, Ault Lending, appeal, ALZN, compliance